Price
$435.64-1.49%Social Signal Score
Analyst Ratings
41 analysts52-week range
- Last close
- $435.64
- Off 52w high
- -9.0%
- 200-day average
- $383.40
- vs 200-day
- +13.6%
Revenue
$10.37B+73.76%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert A. Bradway
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 31,500
- Beta
- 0.42
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.51
Financials
Revenue
$10.37B+73.8%Net Income
$3.86B+99.7%EBITDA
$6.46B+103.8%Free Cash Flow
$3.65B+31.7%EPS (diluted)
$7.08+173.4%Shares Outstanding (diluted)
546.00M-27.0%Operating Expenses
$3.79BCash & Debt
$13.19BReturn of Capital
$1.36BRevenue by Segment (annual)
$35.34BDividend per Share
$2.52Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $36.74B | $7.71B | $14.33 |
| 2024 | $33.42B | $4.09B | $7.62 |
| 2023 | $28.19B | $6.72B | $12.56 |
| 2022 | $26.32B | $6.55B | $12.18 |
| 2021 | $25.98B | $5.89B | $10.34 |
| 2020 | $25.42B | $7.26B | $12.40 |
| 2019 | $23.36B | $7.84B | $12.96 |
| 2018 | $23.75B | $8.39B | $12.70 |
| 2017 | $22.85B | $1.98B | $2.71 |
| 2016 | $22.99B | $7.72B | $10.32 |
| 2015 | $21.66B | $6.94B | $9.15 |
| 2014 | $20.06B | $5.16B | $6.80 |
| 2013 | $18.68B | $5.08B | $6.75 |
| 2012 | $17.27B | $4.34B | $5.61 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AMGN's reported EPS growth of 7.5% a year over 13 years.
- EPS in 5 years
- $20.58
- Implied price
- $473.26
- Return from $443.89
- 1.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $235.29 — -47.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| -2.5% | -13.5% | -10.7% | -8.1% | -5.9% | -3.8% |
| 2.5% | -9.1% | -6.1% | -3.4% | -1.0% | 1.2% |
| 7.5% | -4.7% | -1.5% | 1.3% | 3.8% | 6.1% |
| 12.5% | -0.2% | 3.1% | 6.0% | 8.6% | 11.0% |
| 17.5% | 4.2% | 7.7% | 10.7% | 13.5% | 16.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (100)
- Newszacks.com·2d ago·Neutral
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
View source ↗ - 4chan /biz/biz·4d ago·Positive
>>62921512>>62921498 >You could just buy the top holdings with no fee. Click on the tab that says holdings. Symbol Company % Assets TXN Texas Instruments Incorporated 4.58% COP ConocoPhillips 4.35% CVX Chevron Corporation 4.31% PG The Procter & Gamble Company 4.24% KO The Coca-Cola Company 4.13% AMGN Amgen Inc. 4.08% HD The Home Depot, Inc. 4.01% UNH UnitedHealth Group Incorporated 3.95% MRK Merck & Co., Inc. 3.82% PEP PepsiCo, Inc. 3.79%
View source ↗ - News247wallst.com·5d ago·Negative
Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500 Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high?
View source ↗ - News (RSS)fool·8d ago·Positive
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off harder to call.
View source ↗ - Newsfool.com·9d ago·Positive
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.
View source ↗ - News (RSS)seekingalpha·11d ago·Neutral
Amgen slips after late-stage trial data for Sjögren's disease therapy
View source ↗ - Newsbenzinga.com·11d ago·Negative
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients with Sjögren's disease, a chronic autoimmune disease in which the immune system mistakenly attacks the body's moisture-producing glands.
View source ↗ - Newsreuters.com·11d ago·Negative
Amgen's experimental Sjogren's drug meets late-stage trial goal Amgen's experimental Sjogren's drug meets late-stage trial goal
View source ↗ - Newsprnewswire.com·11d ago·Neutral
…gful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically meaningful improvements in systemic disease activity and symptoms in patients with Sjögren's disease.
View source ↗ - News247wallst.com·12d ago·Neutral
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which one earns a spot in a retirement account.
View source ↗ - News247wallst.com·12d ago·Negative
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.
View source ↗ - News (RSS)thestreet·14d ago·Negative
Amgen's new drug could mean fewer shots for obesity patients An experimental drug from Amgen could reduce 52 injections to just four a year.
View source ↗ - Newsfool.com·14d ago·Positive
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation These are among the best the industry has to offer.
View source ↗ - News247wallst.com·14d ago·Negative
Amgen's Dividend Has Grown 800% Since 2011. Here's What It Pays Today Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon, will hold up.
View source ↗ - News (RSS)fool·17d ago·Positive
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.
View source ↗ - Newsfool.com·17d ago·Positive
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
…lts Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease (ASCVD) and prior statin use.
View source ↗ - Newszacks.com·18d ago·Positive
AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.
View source ↗ - Newszacks.com·18d ago·Neutral
AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.
View source ↗ - News (Marketaux)seekingalpha.com·18d ago·Neutral
Amgen projects 2026 revenue of $38.9B-$39.7B while raising non-GAAP EPS to $22.90-$23.70 (NASDAQ:AMGN) Amgen projects 2026 revenue of $38.9B-$39.7B while raising non-GAAP EPS to $22.90-$23.70 (NASDAQ:AMGN)
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Amgen Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What Amgen (AMGN) Said on Its Q3 Earnings Call Amgen NASDAQ: AMGN reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several late-stage programs. The company raised its full-year revenue and adjusted earnings outlook while highlighting growth in cardiovascular, bone health, inflammation, rare disease, oncology and biosimilar medicines.
View source ↗ - Newszacks.com·19d ago·Neutral
Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·19d ago·Positive
Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates Amgen (AMGN) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $5.64 per share a year ago.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.
View source ↗ - News (RSS)zerohedge·19d ago·Neutral
…ther earnings before the open include Eaton, Marathon Petroleum, Ferrari, Energy Transfer, Sysco, Keurig Dr Pepper, Fiserv and Yum! Brands; AMD, Super Micro, Arista, Amgen and Booking report after the close.Global stocks are trading with little conviction ahead of the looming midterm election results, as Bloomberg's Macro Squawk put it, and in Europe price action is a mirror image of Monday, with cyclicals lagging defensives alongside higher oil prices. Monday's tape was the same story with a ne…
View source ↗ - News (RSS)rte·19d ago·Negative
Operating profits surge by 30% at five star K Club resort Sell-out crowds cheering on Rory McIlroy's dramatic play off Amgen Irish Open win at the K Club last year coincided with operating profits surging by 30% at the five-star golf resort to €3.32m for 2025.
View source ↗ - News (RSS)businessinsider·20d ago·Neutral
Amgen Q3 preview: What to expect
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…tzerland October CPICentral banks: RBA decision, ECB's Radev, Moulin, Kocher, Dolenc, Nagel, Sleijpen and Escriva speak, BoC’s Macklem and Rogers speakEarnings: AMD, Amgen, Arista Networks, Shopify, Pfizer, Eaton, Marathon Petroleum, Intesa Sanpaolo, Booking, Energy Transfer, Ferrari, Apollo, Bayer, Keurig Dr Pepper, BlockOther: UK Chancellor Healey and Treasury ministerial team answer oral questions in the House of CommonsWednesday November 4 Data: US October ISM services, ADP report, September…
View source ↗ - Newszacks.com·20d ago·Neutral
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts? AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…tzerland October CPICentral banks: RBA decision, ECB's Radev, Moulin, Kocher, Dolenc, Nagel, Sleijpen and Escriva speak, BoC's Macklem and Rogers speakEarnings: AMD, Amgen, Arista Networks, Shopify, Pfizer, Eaton, Marathon Petroleum, Intesa Sanpaolo, Booking, Energy Transfer, Ferrari, Apollo, Bayer, Keurig Dr Pepper, BlockOther: UK Chancellor Healey and Treasury ministerial team answer oral questions in the House of CommonsWednesday November 4Data: US October ISM services, ADP report, September …
View source ↗ - Newsfool.com·20d ago·Negative
Amgen Just Gave Its Shareholders Great News Amgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi. The risk of death was cut by 58% for patients who used the combination treatment.
View source ↗ - News (RSS)fool·22d ago·Neutral
Looking For Growth, Income, and Stability? This Stock Could Offer All 3 Amgen can appeal to various kinds of investors.
View source ↗ - Newszacks.com·24d ago·Neutral
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know The latest trading day saw Amgen (AMGN) settling at $460.73, representing a +1.97% change from its previous close.
View source ↗ - Newszacks.com·24d ago·Neutral
Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates Beyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
View source ↗ - News247wallst.com·24d ago·Neutral
Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming? Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned that spending will jump.
View source ↗ - Newsprnewswire.com·25d ago·Neutral
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial markets.
View source ↗ - Newszacks.com·25d ago·Neutral
Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds? Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
View source ↗ - News (RSS)seekingalpha·25d ago·Neutral
Amgen declares $2.52 dividend
View source ↗ - News (RSS)seekingalpha·26d ago·Negative
Amgen receives FDA warning letter over Vectibix ad
View source ↗ - News (RSS)fool·26d ago·Negative
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
View source ↗ - Newsfool.com·26d ago·Negative
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
Amgen: A Biotech Bargain Heading Into Q3 Earnings
View source ↗ - Newsfool.com·26d ago·Positive
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net margin of 33.1%.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Amgen: A Biotech Bargain Heading Into Q3 Earnings On November 3, Amgen Inc. will report its results for Q3. As a reminder, its Q2 non-GAAP EPS rose 25.8% quarter-on-quarter to $6.29, primarily due to the strong performance of biosimilars, Blincyto, and Repatha. On October 24, Amgen released promising results from the DeLLphi-305 study evaluating Imdelltra+Imfinzi in the treatment of extensive-stage small-cell lung cancer.
View source ↗ - Newsprnewswire.com·27d ago·Neutral
AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W.
View source ↗ - News (RSS)fool·28d ago·Positive
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? Both of these biotech stocks could be appealing to income investors.
View source ↗ - Newsfool.com·28d ago·Positive
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? Amgen and Gilead pay forward dividend yields above 2%. Gilead has a lower dividend payout ratio, but Amgen is generating stronger sales growth.
View source ↗ - News (RSS)seekingalpha·28d ago·Positive
Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
View source ↗ - News (RSS)seekingalpha·29d ago·Neutral
Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow
View source ↗ - News (Marketaux)seekingalpha.com·29d ago·Neutral
Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow (NASDAQ:AMGN) 2026-10-24 Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow (NASDAQ:AMGN) 2026-10-24
View source ↗ - Newsseekingalpha.com·29d ago·Positive
Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
View source ↗ - Newsmarketbeat.com·29d ago·Positive
Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study Amgen NASDAQ: AMGN presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance treatment, improved survival outcomes for patients with extensive-stage small-cell lung cancer whose disease had not progressed after initial chemoimmunotherapy.
View source ↗ - News (RSS)fool·29d ago·Positive
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.
View source ↗ - Newsfool.com·29d ago·Positive
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? Amgen focuses on high-growth areas including oncology, inflammation, and rare diseases to drive its clinical pipeline. Johnson & Johnson offers a diversified business model split between innovative medicine and global medical technology.
View source ↗ - Newscnbc.com·29d ago·Negative
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. Full results from a late-stage trial show that adding Amgen's Imdelltra to AstraZeneca's Imfinzi drug slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer.
View source ↗ - Newszacks.com·30d ago·Neutral
Here's Why Amgen (AMGN) Fell More Than Broader Market Amgen (AMGN) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day.
View source ↗ - News (RSS)fool·30d ago·Neutral
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.
View source ↗ - Newszacks.com·31d ago·Positive
Amgen (AMGN) Gains As Market Dips: What You Should Know Amgen (AMGN) closed at $447.28 in the latest trading session, marking a +2.04% move from the prior day.
View source ↗ - Newsfool.com·31d ago·Negative
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026? Amgen maintains a diverse portfolio focused on oncology, rare diseases, and inflammation while providing steady cash flow generation. Eli Lilly & Co. continues to see explosive growth driven by its dominant position in the cardiometabolic and incretin drug markets.
View source ↗ - News (RSS)fool·32d ago·Positive
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.
View source ↗ - Newsfool.com·33d ago·Positive
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Amgen is demonstrating strong top-line growth driven by a diverse portfolio in oncology and rare diseases. Bristol Myers Squibb remains a heavy producer of free cash flow while offering a significantly lower valuation.
View source ↗ - Newsprnewswire.com·33d ago·Neutral
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m.
View source ↗ - News (RSS)investing·33d ago·Neutral
Amgen, AstraZeneca report positive trial results for Tezspire in EoE
View source ↗ - News247wallst.com·33d ago·Negative
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up 4% to $1,295.
View source ↗ - Newsprnewswire.com·33d ago·Negative
…l Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52 THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52 in adolescent and adult patie…
View source ↗ - News (Marketaux)gurufocus.com·34d ago·Positive
Is AMGN Overvalued? DCF Says Worth $189 On October 19, 2026, we conducted a DCF [+235 characters]
View source ↗ - Newszacks.com·34d ago·Neutral
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - News (RSS)rte·37d ago·Negative
Property owners at Trump Doonbeg see post Open dividend Property owners at the Trump Doonbeg golf resort in Co Clare are already reaping the dividends of the staging of the Amgen Irish Open with a luxury cottage recently selling for €910,000.
View source ↗ - Newszacks.com·38d ago·Neutral
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.
View source ↗ - Newsinvestopedia.com·38d ago·Positive
These Consumer Stocks Are Getting a Lift as Investors Rotate Out of Tech Some beaten-down consumer names are getting a boost as investors pull back from tech stocks.
View source ↗ - News247wallst.com·38d ago·Neutral
AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.
View source ↗ - Newszacks.com·40d ago·Positive
Here's Why Amgen (AMGN) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)fool·42d ago·Neutral
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.
View source ↗ - Newszacks.com·44d ago·Negative
Amgen (AMGN) Laps the Stock Market: Here's Why In the closing of the recent trading day, Amgen (AMGN) stood at $414.87, denoting a +1.82% move from the preceding trading day.
View source ↗ - Newszacks.com·46d ago·Negative
Amgen (AMGN) Advances While Market Declines: Some Information for Investors In the closing of the recent trading day, Amgen (AMGN) stood at $413.08, denoting a +2.6% move from the preceding trading day.
View source ↗ - Newszacks.com·47d ago·Neutral
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - News (RSS)zerohedge·48d ago·Neutral
… asked. ZeroHedge detailed the fight over the review in May. Still on sale Tavneos is still on sale in the US, five months after Høeg's drug center moved to pull it. Amgen's pill for a rare autoimmune disease of the blood vessels was approved in 2021 on the strength of a single pivotal trial. The FDA had told its developer that the trial had to show the drug beat steroids at 52 weeks. In January, the FDA asked Amgen to withdraw it voluntarily. Amgen declined. In April, the agency formally propos…
View source ↗ - News (RSS)fool·49d ago·Positive
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
View source ↗ - Newsfool.com·49d ago·Positive
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Amgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market and is expanding into high-growth gene therapies.
View source ↗ - News (RSS)seekingalpha·50d ago·Neutral
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot
View source ↗ - Newszacks.com·52d ago·Positive
Amgen (AMGN) Stock Dips While Market Gains: Key Facts Amgen (AMGN) closed at $407.27 in the latest trading session, marking a -3.38% move from the prior day.
View source ↗ - Newszacks.com·52d ago·Negative
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
View source ↗ - News (Marketaux)gurufocus.com·53d ago·Positive
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors On September 29, 2026, Amgen <e[+239 characters]
View source ↗ - News247wallst.com·54d ago·Negative
Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
View source ↗ - Newsfool.com·57d ago·Neutral
2 Healthcare Stocks That Just Delivered Great News for Investors Vertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates. Both companies have robust businesses and strong medium-term prospects.
View source ↗ - Newszacks.com·58d ago·Neutral
Amgen (AMGN) Rises Higher Than Market: Key Facts In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day.
View source ↗ - Newszacks.com·58d ago·Neutral
Bet on These 5 Dividend Growth Stocks Amid Rising Treasury Yields Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth.
View source ↗ - Newszacks.com·58d ago·Neutral
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newsproactiveinvestors.com·60d ago·Negative
Amgen price target raised by Jefferies to $410 after positive Sjögren's data Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically meaningful improvement in the primary endpoint, the change from baseline in ESSDAI at week 48.
View source ↗ - Newszacks.com·60d ago·Neutral
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
View source ↗ - News (RSS)investing·61d ago·Neutral
Amgen, Vicor among market cap stock movers on Tuesday
View source ↗ - Newsbenzinga.com·61d ago·Neutral
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data Amgen Inc. (NASDAQ:AMGN) has reported encouraging topline outcomes from its Phase 3 OASIZ 301 study. The trial assessed the efficacy of dazodalibep in adult patients suffering from Sjögren's disease accompanied by moderate-to-severe systemic disease activity.
View source ↗ - Newsreuters.com·61d ago·Negative
Amgen's autoimmune drug succeeds in late-stage trial Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
View source ↗ - Newsprnewswire.com·61d ago·Neutral
… Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.
View source ↗ - News (RSS)thestreet·61d ago·Negative
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market's.
View source ↗ - Newszacks.com·62d ago·Positive
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.
View source ↗ - News (Marketaux)finance.yahoo.com·64d ago·Positive
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story? Quick Read Amgen (AMGN) yields[+291 characters]
View source ↗
Earnings
Tue, Feb 2(in 2 months)
Consensus estimate $5.61 per share
Typical surprise +11.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$6.45 vs $5.79beat
- Tue, Aug 4$6.29 vs $5.62beat
- Thu, Apr 30$5.15 vs $4.77beat
- Tue, Feb 3$5.29 vs $4.73beat
- Tue, Nov 4$5.64 vs $5.02beat
- Tue, Aug 5$6.02 vs $5.28beat
Estimates and results for AMGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMGN officers and directors.
- Bought
- —
- Sold
- $2.9m
0 trades
5 trades
- Khosla Rachnasold
- Khosla Rachnasold
- Miller Dereksold
- Grygiel Nancy A.sold
- Grygiel Nancy A.sold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- David Taylorhouse · OH02 · disclosed Nov 13, 2026 (10d later)Sell$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Nov 13, 2026 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Sheldon Whitehousesenate · RI · disclosed Nov 2, 2026 (18d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Oct 2, 2026 (10d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Sep 7, 2026 (12d later)Sell$1,001 - $15,000
- Sheldon Whitehousesenate · RI · disclosed Sep 2, 2026 (21d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Aug 5, 2026 (477d later)Sell$15,001 - $50,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jul 8, 2026 (36d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Jun 15, 2026 (10d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed May 11, 2026 (24d later)Sell$15,001 - $50,000
- Mark Warnersenate · VA · disclosed May 1, 2026 (25d later)Sell$1,001 - $15,000
- Mark Warnersenate · VA · disclosed May 1, 2026 (24d later)Sell$1,001 - $15,000
- Mark Warnersenate · VA · disclosed May 1, 2026 (24d later)Sell$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Apr 22, 2026 (29d later)Buy$15,001 - $50,000
- David Taylorhouse · OH02 · disclosed Mar 9, 2026 (11d later)Sell$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Feb 3, 2026 (5d later)Sell$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Feb 3, 2026 (18d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
